Achieve Life Sciences Inc. (ACHV)’s Financial Results Comparing With Ascendis Pharma A/S (NASDAQ:ASND)

Achieve Life Sciences Inc. (NASDAQ:ACHV) and Ascendis Pharma A/S (NASDAQ:ASND), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achieve Life Sciences Inc. N/A 0.00 12.79M -8.12 0.00
Ascendis Pharma A/S N/A 0.00 N/A -3.81 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Achieve Life Sciences Inc. and Ascendis Pharma A/S.

Profitability

Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Achieve Life Sciences Inc. 0.00% -114.6% -93.5%
Ascendis Pharma A/S 0.00% -45.2% -41.3%

Risk & Volatility

Achieve Life Sciences Inc. has a 2.78 beta, while its volatility is 178.00% which is more volatile than S&P 500. Competitively, Ascendis Pharma A/S’s 9.00% volatility makes it less volatile than S&P 500, because of the 0.91 beta.

Liquidity

The Current Ratio and Quick Ratio of Achieve Life Sciences Inc. are 4.6 and 4.6 respectively. Its competitor Ascendis Pharma A/S’s Current Ratio is 10.5 and its Quick Ratio is 10.5. Ascendis Pharma A/S can pay off short and long-term obligations better than Achieve Life Sciences Inc.

Analyst Ratings

Recommendations and Ratings for Achieve Life Sciences Inc. and Ascendis Pharma A/S can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Achieve Life Sciences Inc. 0 0 0 0.00
Ascendis Pharma A/S 0 0 5 3.00

Competitively Ascendis Pharma A/S has an average price target of $153.8, with potential upside of 19.98%.

Insider and Institutional Ownership

Institutional investors held 26.7% of Achieve Life Sciences Inc. shares and 95.7% of Ascendis Pharma A/S shares. About 4.97% of Achieve Life Sciences Inc.’s share are held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Achieve Life Sciences Inc. -8.68% 61.33% 45.78% -23.66% -80.94% 100%
Ascendis Pharma A/S 61.55% 68.77% 97.38% 58.5% 89.47% 92.5%

For the past year Achieve Life Sciences Inc. was more bullish than Ascendis Pharma A/S.

Summary

Ascendis Pharma A/S beats on 6 of the 7 factors Achieve Life Sciences Inc.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.